Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ascendis Pharma A/S

161.52
+7.094.59%
Pre-market: 162.521.00+0.62%08:33 EDT
Volume:495.60K
Turnover:79.08M
Market Cap:9.75B
PE:-25.66
High:162.30
Open:155.20
Low:154.64
Close:154.43
Loading ...

TD Cowen Sticks to Its Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
05 Mar

Exploring US High Growth Tech Stocks In March 2025

Simply Wall St.
·
04 Mar

Ascendis Pharma (ASND) Receives a Hold from Morgan Stanley

TIPRANKS
·
03 Mar

Ascendis Pharma Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
25 Feb

Morgan Stanley Sticks to Their Hold Rating for Ascendis Pharma (ASND)

TIPRANKS
·
24 Feb

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Medtronic (MDT) and Tyra Bioscience (TYRA)

TIPRANKS
·
19 Feb

European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading

MT Newswires Live
·
19 Feb

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
18 Feb

Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.
·
15 Feb

Ascendis Pharma Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
14 Feb

Evercore ISI Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
14 Feb

Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...

GuruFocus.com
·
14 Feb

Ascendis Pharma A/S Earnings Call Highlights Growth and Challenges

TIPRANKS
·
14 Feb

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Benzinga
·
14 Feb

European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading

MT Newswires Live
·
14 Feb

Ascendis Pharma Is Maintained at Overweight by JP Morgan

Dow Jones
·
14 Feb

Stock Track | Ascendis Pharma Soars Over 11% on Upbeat Q4 Results, Share Buyback Plan

Stock Track
·
13 Feb

Stock Track | Ascendis Pharma Soars Over 8% Pre-Market on Strong Q4 Earnings, Buyback Plan

Stock Track
·
13 Feb

Ascendis Pharma (ASND) Receives a Buy from J.P. Morgan

TIPRANKS
·
13 Feb

Ascendis Pharma price target lowered to $192 from $203 at BofA

TIPRANKS
·
13 Feb